Globalization of clinical trials is the result of the U.S. Pharma business actively entering international markets, demand for higher patient population size, ICH-GCP principles implementation worldwide, cost effectiveness, and many other reasons. Among all the regions, emerging markets such as China, Brazil, India, Asia Pacific, Russia and Eastern Europe became very popular to place clinical studies.

Last week Nataliya Katsnelson, GCT Senior Business Development Manager presented on the topic of acceptance of the data from foreign investigations by the U.S. FDA during 22nd Annual Eurasian — American Innovation Technology Week (RANIT) Seminar Sessions at the Hermes Expo.

GCT would like to thank the organizer of series regional industry events, the Mid-Atlantic — Eurasia Business Council President Val Kogan